Ionis Pharmaceuticals logo

Ionis Pharmaceuticals (IONS) Q1 2026 Earnings

IONS·Reported April 29, 2026·Before market open

Ionis Pharmaceuticals reported Q1 2026 revenue of $246.0M (+86.9% YoY), beat analyst consensus of $195.6M by $50.4M. Diluted EPS came in at $-0.56 (+25.3% YoY), beat the $-0.85 consensus by $0.29.

Revenue
$246.0Mbeat by $50.4M
Consensus: $195.6M
Diluted EPS
$-0.56beat by $0.29
Consensus: $-0.85
SEC

SEC Filings

Earnings release8-K · 0001140361-26-017637
Quarterly report10-Q · 0000874015-26-000177

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Ionis Pharmaceuticals's Q1 2026 earnings report.

Ionis Pharmaceuticals (IONS) reported Q1 2026 earnings on April 29, 2026 before market open.

Ionis Pharmaceuticals reported revenue of $246.0M and diluted EPS of $-0.56 for Q1 2026.

Revenue beat the consensus estimate of $195.6M by $50.4M. EPS beat the consensus estimate of $-0.85 by $0.29.

Compared to the same quarter a year prior, revenue grew 86.9% from $131.6M a year earlier and diluted EPS grew 25.3% from $-0.75.

You can read the 8-K earnings release (0001140361-26-017637) and the 10-Q periodic report (0000874015-26-000177) directly on SEC EDGAR. The filing index links above go to sec.gov.